Norouzi Mohammad, Hardy Pierre
Department of Pharmacology, University of Montréal, CHU Sainte-Justine Research Centre, Montréal, H3T 1C5, Canada.
Departments of Pediatrics, Pharmacology and Physiology, University of Montréal, CHU Sainte-Justine Research Centre, Montréal, H3T 1C5, Canada.
Acta Biomater. 2021 Feb;121:134-142. doi: 10.1016/j.actbio.2020.12.009. Epub 2020 Dec 7.
Lung cancer is the leading cause of cancer mortality worldwide. Owing to a lack of early-stage diagnosis, most lung cancers are detected in advanced stages, limiting the available therapeutic options. Moreover, extensive systemic chemotherapy of lung tumors is often associated with severe off-target toxicity and drug resistance of cancer cells, thus diminishing the outcomes of chemotherapy modalities. In this light, nanomedicines have opened an alternative avenue to develop more efficacious therapeutic platforms while addressing several current challenges. Clinical findings have revealed that nanomedicines improve the pharmacokinetics and biodistribution of the therapeutic agents while decreasing their systemic toxicity. This review provides an update on nanomedicines that have been clinically approved or are undergoing clinical trials for treatment of lung cancer. By discussing the clinical findings of the current nanoformulations, this review provides prospects for the development of more efficacious nanomedicines to improve the clinical outcomes of lung cancer treatment.
肺癌是全球癌症死亡的主要原因。由于缺乏早期诊断，大多数肺癌在晚期才被发现，这限制了可用的治疗选择。此外，肺癌的广泛全身化疗通常与严重的脱靶毒性和癌细胞耐药性相关，从而降低了化疗方式的疗效。有鉴于此，纳米药物开辟了一条替代途径，以开发更有效的治疗平台，同时应对当前的若干挑战。临床研究结果表明，纳米药物可改善治疗药物的药代动力学和生物分布，同时降低其全身毒性。本综述提供了已获临床批准或正在进行肺癌治疗临床试验的纳米药物的最新信息。通过讨论当前纳米制剂的临床研究结果，本综述为开发更有效的纳米药物以改善肺癌治疗的临床结果提供了前景。
